Phaseline

Targets › INSTI

INSTI: drug programs, companies and trials

7 programs from 2 companies in 50 trials: 19 Phase 3, 13 Phase 1, 10 Phase 4, 8 Phase 2; Infectious disease, Other, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: the race on INSTI, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKFostemsavir
Envelope polyprotein GP160 inhibitor
INSTI, GP120, CD4Phase 3HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant VirusJan 2027
GSKCabotegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, INTEGRASEPhase 3HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia …Mar 2027
GSKDolutegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, RTASE, INTEGRASE, RTPhase 3HIV; HIV Infections; HIV-1-infection; Acute HIV Infection …Mar 2027
GSKCAB ULA
Integrase strand transfer inhibitor (ultra-long-acting formulation)
INSTIPhase 3HIV InfectionsSep 2029
Professor Francois VenterDelstrigo (DOR/3TC/TDF)
Non-nucleoside reverse transcriptase inhibitor (doravirine) with nucleoside reverse transc
INSTI, NNRTIPhase 3HIV-1-infection–
Professor Francois VenterKOCITAF (DTG/TAF/FTC)
Integrase strand transfer inhibitor (dolutegravir) with nucleotide and nucleoside reverse
INSTIPhase 3HIV-1-infection–
GSKVH4367310
Cabotegravir prodrug
INSTIPhase 1HIV InfectionsDec 2028

Conditions

HIV Infections (24) HIV-1-infection (10) HIV (4) Infection, Human Immunodeficiency Virus (1) Pre-exposure Prophylaxis (1) HIV-1 Infected Adults With Controlled Viremia (1) Pre-Exposure Prophylaxis (PrEP) (1) HIV -1 Infection (1) Hiv (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1) Acute HIV Infection (1)

Modalities

small molecule (5), mixed (2)

Companies

GSK (5) Professor Francois Venter (2)

Related targets

INTEGRASE (2) GP120 (1) CD4 (1) RTASE (1) RT (1) NNRTI (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.